Symbols / VTYX $14.00 +0.00%
VTYX Chart
About
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.00B |
| Enterprise Value | 816.41M | Income | -106.61M | Sales | — |
| Book/sh | 2.68 | Cash/sh | 2.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 83 | IPO | Oct 21, 2021 |
| P/E | — | Forward P/E | -8.94 | PEG | — |
| P/S | — | P/B | 5.22 | P/C | — |
| EV/EBITDA | -7.01 | EV/Sales | — | Quick Ratio | 17.15 |
| Current Ratio | 17.86 | Debt/Eq | 5.24 | LT Debt/Eq | — |
| EPS (ttm) | -1.49 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -28.46% |
| ROE | -45.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 71.75M |
| Shs Float | 47.85M | Short Float | 6.93% | Short Ratio | 1.84 |
| Short Interest | — | 52W High | 25.00 | 52W Low | 0.78 |
| Beta | 1.27 | Avg Volume | 3.62M | Volume | 5.40M |
| Target Price | $13.00 | Recom | Hold | Prev Close | $14.00 |
| Price | $14.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.00
Mean price target
2. Current target
$14.00
Latest analyst target
3. DCF / Fair value
$-11.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.00
Low
$9.00
High
$14.00
Mean
$13.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-08 | down | Oppenheimer | Outperform → Perform | — |
| 2026-01-08 | down | Wells Fargo | Overweight → Equal-Weight | $14 |
| 2026-01-08 | down | HC Wainwright & Co. | Buy → Neutral | $14 |
| 2026-01-08 | down | UBS | Buy → Neutral | $14 |
| 2026-01-08 | down | LifeSci Capital | Outperform → Market Perform | $14 |
| 2026-01-08 | down | Canaccord Genuity | Buy → Hold | $14 |
| 2026-01-07 | init | UBS | — → Buy | $20 |
| 2025-11-07 | main | Canaccord Genuity | Buy → Buy | $16 |
| 2025-11-07 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2025-11-05 | up | HC Wainwright & Co. | Neutral → Buy | $18 |
| 2025-10-27 | main | Oppenheimer | Outperform → Outperform | $14 |
| 2025-10-01 | init | Clear Street | — → Buy | $11 |
| 2025-01-14 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-11-08 | reit | Oppenheimer | Outperform → Outperform | $9 |
| 2024-10-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-09-23 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-08-12 | main | Wells Fargo | Overweight → Overweight | $11 |
| 2024-08-12 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2024-07-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
- [15-12G] Ventyx Biosciences, Inc. SEC Filing - Stock Titan Mon, 16 Mar 2026 16
- Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple - Yahoo Finance Sun, 25 Jan 2026 08
- $VTYX stock is up 48% today. Here's what we see in our data. - Quiver Quantitative Wed, 07 Jan 2026 08
- VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know - November 18, 2025 - Zacks Investment Research ue, 18 Nov 2025 08
- M&A News: Ventyx Biosciences Stock (VTYX) Rallies on News of Potential Acquisition by Eli Lilly - TipRanks Wed, 07 Jan 2026 08
- Ventyx Biosciences Stock Pre-Market (+63%) : Unconfirmed LLY Takeover Rumors - Trefis Wed, 07 Jan 2026 08
- Ventyx Biosciences stock surges after Eli Lilly acquisition talks - Investing.com ue, 06 Jan 2026 08
- Biggest stock movers Wednesday: GME, VTYX, MBLY, and more - Seeking Alpha Wed, 07 Jan 2026 08
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX - PR Newswire hu, 15 Jan 2026 08
- Ventyx Biosciences (Nasdaq: VTYX) schedules Jefferies London fireside chat on Nov. 19 - Stock Titan Mon, 17 Nov 2025 08
- Ventyx Biosciences, Inc. (VTYX) Is Up 20.81% in One Week: What You Should Know - Yahoo Finance hu, 09 Oct 2025 07
- Ventyx stock soars after positive Phase 2 results for inflammation drug - Investing.com Wed, 22 Oct 2025 07
- Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts - TipRanks hu, 08 Jan 2026 08
- Ventyx Biosciences (VTYX) exec records option dispositions in $14 Lilly buyout - Stock Titan Wed, 04 Mar 2026 21
- With 57% ownership, Ventyx Biosciences, Inc. (NASDAQ:VTYX) boasts of strong institutional backing - Yahoo Finance Mon, 24 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 694718 | 9705210.0 | — | Purchase at price 13.97 per share. | SUBRAMANIAM SOMU | Director | — | 2026-02-27 00:00:00 | I |
| 1 | 47345 | 365461.0 | — | Sale at price 7.72 per share. | MOHAN RAJU | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 2 | 12675 | 97840.0 | — | Sale at price 7.72 per share. | NUSS JOHN M. PH.D. | Officer | — | 2025-12-18 00:00:00 | D |
| 3 | 116668 | nan | — | — | MOHAN RAJU | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 4 | 34930 | nan | — | — | NUSS JOHN M. PH.D. | Officer | — | 2025-12-17 00:00:00 | D |
| 5 | 3000 | 28500.0 | — | Stock Award(Grant) at price 9.50 per share. | FORMAN MARK S M.D., PH.D. | Officer | — | 2025-11-17 00:00:00 | D |
| 6 | 1767 | 16786.0 | — | Stock Award(Grant) at price 9.50 per share. | GONZALES ROY M. | Officer | — | 2025-11-17 00:00:00 | D |
| 7 | 3000 | 3090.0 | — | Stock Award(Grant) at price 1.03 per share. | FORMAN MARK S M.D., PH.D. | Officer | — | 2025-05-15 00:00:00 | D |
| 8 | 1750 | 1802.0 | — | Stock Award(Grant) at price 1.03 per share. | GONZALES ROY M. | Officer | — | 2025-05-15 00:00:00 | D |
| 9 | 1887 | 2019.0 | — | Sale at price 1.07 per share. | NUSS JOHN M. PH.D. | Officer | — | 2025-04-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -147.10M | -207.05M | -112.67M | -72.57M |
| TotalUnusualItems | -11.05M | |||
| TotalUnusualItemsExcludingGoodwill | -11.05M | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -135.12M | -192.96M | -108.43M | -83.75M |
| ReconciledDepreciation | 1.35M | 941.00K | 470.00K | 30.00K |
| EBITDA | -147.10M | -207.05M | -112.67M | -83.62M |
| EBIT | -148.45M | -207.99M | -113.14M | -83.65M |
| NetInterestIncome | 13.42M | 15.07M | 4.67M | -21.00K |
| InterestExpense | 0.00 | 99.00K | ||
| InterestIncome | 13.42M | 15.07M | 4.67M | 78.00K |
| NormalizedIncome | -135.12M | -192.96M | -108.43M | -72.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -135.12M | -192.96M | -108.43M | -83.75M |
| TotalExpenses | 148.45M | 207.99M | 113.14M | 67.15M |
| TotalOperatingIncomeAsReported | -148.45M | -207.99M | -113.14M | -67.15M |
| DilutedAverageShares | 68.48M | 58.54M | 52.47M | 12.83M |
| BasicAverageShares | 68.48M | 58.54M | 52.47M | 12.83M |
| DilutedEPS | -1.97 | -3.30 | -2.07 | -6.65 |
| BasicEPS | -1.97 | -3.30 | -2.07 | -6.65 |
| DilutedNIAvailtoComStockholders | -135.12M | -192.96M | -108.43M | -85.30M |
| NetIncomeCommonStockholders | -135.12M | -192.96M | -108.43M | -85.30M |
| PreferredStockDividends | 1.55M | |||
| NetIncome | -135.12M | -192.96M | -108.43M | -83.75M |
| NetIncomeIncludingNoncontrollingInterests | -135.12M | -192.96M | -108.43M | -83.75M |
| NetIncomeContinuousOperations | -135.12M | -192.96M | -108.43M | -83.75M |
| PretaxIncome | -135.12M | -192.96M | -108.43M | -83.75M |
| OtherIncomeExpense | -88.00K | -42.00K | 41.00K | -16.58M |
| OtherNonOperatingIncomeExpenses | -88.00K | -42.00K | 41.00K | -5.53M |
| GainOnSaleOfSecurity | -11.05M | |||
| NetNonOperatingInterestIncomeExpense | 13.42M | 15.07M | 4.67M | -21.00K |
| InterestExpenseNonOperating | 0.00 | 99.00K | ||
| InterestIncomeNonOperating | 13.42M | 15.07M | 4.67M | 78.00K |
| OperatingIncome | -148.45M | -207.99M | -113.14M | -67.15M |
| OperatingExpense | 148.45M | 207.99M | 113.14M | 67.15M |
| ResearchAndDevelopment | 117.00M | 175.77M | 87.74M | 58.48M |
| SellingGeneralAndAdministration | 31.45M | 32.23M | 25.40M | 8.67M |
| GeneralAndAdministrativeExpense | 31.45M | 32.23M | 25.40M | 8.67M |
| OtherGandA | 31.45M | 32.23M | 25.40M | 8.67M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.13M | 59.24M | 56.98M | 50.41M |
| ShareIssued | 71.13M | 59.24M | 56.98M | 50.41M |
| TotalDebt | 10.79M | 12.51M | 1.56M | 0.00 |
| TangibleBookValue | 254.04M | 243.92M | 353.89M | 279.20M |
| InvestedCapital | 254.04M | 243.92M | 353.89M | 279.20M |
| WorkingCapital | 216.85M | 242.08M | 314.33M | 250.74M |
| NetTangibleAssets | 254.04M | 243.92M | 353.89M | 279.20M |
| CapitalLeaseObligations | 10.79M | 12.51M | 1.56M | 0.00 |
| CommonStockEquity | 254.04M | 243.92M | 353.89M | 279.20M |
| TotalCapitalization | 254.04M | 243.92M | 353.89M | 279.20M |
| TotalEquityGrossMinorityInterest | 254.04M | 243.92M | 353.89M | 279.20M |
| StockholdersEquity | 254.04M | 243.92M | 353.89M | 279.20M |
| GainsLossesNotAffectingRetainedEarnings | 157.00K | -50.00K | -1.12M | -58.00K |
| OtherEquityAdjustments | 157.00K | -50.00K | -1.12M | -58.00K |
| RetainedEarnings | -554.31M | -419.19M | -226.22M | -117.80M |
| AdditionalPaidInCapital | 808.19M | 663.15M | 581.24M | 397.05M |
| CapitalStock | 7.00K | 6.00K | 6.00K | 5.00K |
| CommonStock | 7.00K | 6.00K | 6.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 22.52M | 33.77M | 17.50M | 12.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.74M | 11.51M | 1.15M | 0.00 |
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 9.74M | 11.51M | 1.15M | 0.00 |
| LongTermCapitalLeaseObligation | 9.74M | 11.51M | 1.15M | 0.00 |
| CurrentLiabilities | 12.78M | 22.27M | 16.36M | 12.28M |
| CurrentDebtAndCapitalLeaseObligation | 1.05M | 1.00M | 412.00K | |
| CurrentCapitalLeaseObligation | 1.05M | 1.00M | 412.00K | 0.00 |
| PayablesAndAccruedExpenses | 11.72M | 21.26M | 15.95M | 12.28M |
| CurrentAccruedExpenses | 8.59M | 15.51M | 9.51M | 7.62M |
| Payables | 3.13M | 5.76M | 6.43M | 4.66M |
| AccountsPayable | 3.13M | 5.76M | 6.43M | 4.66M |
| TotalAssets | 276.56M | 277.69M | 371.40M | 291.48M |
| TotalNonCurrentAssets | 46.94M | 13.35M | 40.71M | 28.46M |
| OtherNonCurrentAssets | 1.03M | 1.08M | 96.00K | 60.00K |
| InvestmentsAndAdvances | 35.62M | 0.00 | 38.67M | 28.15M |
| OtherInvestments | 28.15M | |||
| InvestmentinFinancialAssets | 35.62M | 0.00 | 38.67M | 28.15M |
| AvailableForSaleSecurities | 35.62M | 38.67M | 28.15M | |
| NetPPE | 10.28M | 12.27M | 1.94M | 254.00K |
| AccumulatedDepreciation | -470.00K | -259.00K | -95.00K | -24.00K |
| GrossPPE | 10.75M | 12.53M | 2.04M | 278.00K |
| Leases | 283.00K | 0.00 | ||
| ConstructionInProgress | 15.00K | 157.00K | 0.00 | |
| OtherProperties | 9.81M | 11.69M | 1.68M | 134.00K |
| MachineryFurnitureEquipment | 641.00K | 686.00K | 360.00K | 144.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 229.62M | 264.35M | 330.69M | 263.02M |
| OtherCurrentAssets | 12.30M | 12.12M | 12.75M | 4.44M |
| PrepaidAssets | 4.44M | |||
| CashCashEquivalentsAndShortTermInvestments | 217.32M | 252.22M | 317.94M | 258.58M |
| OtherShortTermInvestments | 190.06M | 200.64M | 253.12M | 187.78M |
| CashAndCashEquivalents | 27.26M | 51.58M | 64.82M | 70.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -131.11M | -167.04M | -99.05M | -38.91M |
| IssuanceOfDebt | 0.00 | 450.00K | ||
| IssuanceOfCapitalStock | 121.65M | 48.41M | 165.40M | 323.04M |
| CapitalExpenditure | -241.00K | -514.00K | -275.00K | -262.00K |
| IncomeTaxPaidSupplementalData | 3.00K | |||
| EndCashPosition | 28.23M | 52.55M | 64.82M | 70.79M |
| BeginningCashPosition | 52.55M | 64.82M | 70.79M | 244.00K |
| EffectOfExchangeRateChanges | -55.00K | -12.00K | -42.00K | 11.00K |
| ChangesInCash | -24.26M | -12.25M | -5.93M | 70.54M |
| FinancingCashFlow | 122.11M | 53.33M | 167.77M | 323.55M |
| CashFlowFromContinuingFinancingActivities | 122.11M | 53.33M | 167.77M | 323.55M |
| ProceedsFromStockOptionExercised | 466.00K | 4.92M | 2.37M | 65.00K |
| NetPreferredStockIssuance | 26.60M | 0.00 | 0.00 | 164.22M |
| PreferredStockIssuance | 26.60M | 0.00 | 0.00 | 164.22M |
| NetCommonStockIssuance | 95.05M | 48.41M | 165.40M | 158.81M |
| CommonStockIssuance | 95.05M | 48.41M | 165.40M | 158.81M |
| NetIssuancePaymentsOfDebt | 0.00 | 450.00K | ||
| NetLongTermDebtIssuance | 0.00 | 450.00K | ||
| LongTermDebtIssuance | 0.00 | 450.00K | ||
| InvestingCashFlow | -15.51M | 100.94M | -74.93M | -214.37M |
| CashFlowFromContinuingInvestingActivities | -15.51M | 100.94M | -74.93M | -214.37M |
| NetInvestmentPurchaseAndSale | -15.27M | 101.45M | -74.66M | -216.00M |
| SaleOfInvestment | 268.38M | 373.73M | 272.58M | 16.50M |
| PurchaseOfInvestment | -283.65M | -272.27M | -347.24M | -232.50M |
| NetBusinessPurchaseAndSale | 0.00 | 1.90M | ||
| SaleOfBusiness | 0.00 | 1.90M | ||
| NetPPEPurchaseAndSale | -241.00K | -514.00K | -275.00K | -262.00K |
| PurchaseOfPPE | -241.00K | -514.00K | -275.00K | -262.00K |
| OperatingCashFlow | -130.87M | -166.52M | -98.77M | -38.65M |
| CashFlowFromContinuingOperatingActivities | -130.87M | -166.52M | -98.77M | -38.65M |
| ChangeInWorkingCapital | -10.56M | 5.81M | -5.16M | 4.02M |
| ChangeInOtherCurrentLiabilities | -847.00K | -59.00K | -326.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -9.56M | 5.25M | 3.50M | 8.40M |
| ChangeInAccruedExpense | -6.91M | 5.99M | 1.89M | 5.96M |
| ChangeInPayable | -2.64M | -745.00K | 1.61M | 2.44M |
| ChangeInAccountPayable | -2.64M | -745.00K | 1.61M | 2.44M |
| ChangeInPrepaidAssets | -159.00K | 616.00K | -8.34M | -4.39M |
| OtherNonCashItems | -88.00K | 27.27M | ||
| StockBasedCompensation | 22.93M | 28.59M | 16.57M | 2.73M |
| AssetImpairmentCharge | 0.00 | 285.00K | 0.00 | |
| AmortizationOfSecurities | -9.52M | -9.18M | -2.23M | 0.00 |
| DepreciationAmortizationDepletion | 1.35M | 941.00K | 470.00K | 30.00K |
| DepreciationAndAmortization | 1.35M | 941.00K | 470.00K | 30.00K |
| Depreciation | 1.35M | 941.00K | 470.00K | 30.00K |
| OperatingGainsLosses | 136.00K | 11.05M | ||
| GainLossOnInvestmentSecurities | 11.05M | |||
| GainLossOnSaleOfPPE | 136.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -135.12M | -192.96M | -108.43M | -83.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VTYX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|